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Simple Summary: Cancer metastasis significantly contributes to cancer-related mortality. Our
retrospective cohort study aimed to evaluate the mutational landscape of seven solid metastatic
tumors and mutational effects on survival using a single molecular testing panel. Additionally, we
assessed the treatments used in advanced cancer. We identified somatic mutations that were mutually
exclusive in seven gene pairs. Among them, somatic mutations in APC and CDKN2A showed an
opposite effect on overall survival (OS). Longer OS was associated with metastatic cases diagnosed
post-2015. Progression-free survival was associated with the use of targeted treatments. Our results
highlight complex interactions of mutational landscape with a single molecular test, time of metastatic
diagnosis, and the impact of targeted therapy usage on survival using a pan-cancer cohort.
Abstract: Metastasis continues to be the primary cause of all cancer-related deaths despite the recent
advancements in cancer treatments. To evaluate the role of mutations in overall survival (OS) and
treatment outcomes, we analyzed 957 metastatic patients with seven major cancer types who had
available molecular testing results with a FoundationOne CDx® panel. The most prevalent genes
with somatic mutations were TP53, KRAS, APC, and LRP1B. In this analysis, these genes had mutation
frequencies higher than in publicly available datasets. We identified that the somatic mutations were
seven mutually exclusive gene pairs and an additional fifty-two co-occurring gene pairs. Mutations
in the mutually exclusive gene pair APC and CDKN2A showed an opposite effect on the overall
survival. However, patients with CDKN2A mutations showed significantly shorter OS (HR: 1.72,
95% CI: 1.34–2.21, p < 0.001) after adjusting for cancer type, age at diagnosis, and sex. Five-year post
metastatic diagnosis survival analysis showed a significant improvement in OS (median survival 28
and 43 months in pre-2015 and post-2015 metastatic diagnosis, respectively, p = 0.00021) based on
the year of metastatic diagnosis. Although the use of targeted therapies after metastatic diagnosis
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prolonged OS, the benefit was not statistically significant. However, longer five-year progression-free
survival (PFS) was significantly associated with targeted therapy use (median 10.9 months (CI:
9.7–11.9 months) compared to 9.1 months (CI: 8.1–10.1 months) for non-targeted therapy, respectively,
p = 0.0029). Our results provide a clinically relevant overview of the complex molecular landscape
and survival mechanisms in metastatic solid cancers.
Keywords: metastatic solid tumors; somatic mutations; overall survival; progression-free survival;
molecular testing; targeted therapies
1. Introduction
Despite recent advances in targeted therapies, metastatic cancer continues to be
one of the main causes of morbidity and mortality worldwide. Cancer results from the
accumulation of mutations. The phenotypic features and survival outcomes of cancer can
be linked to the mutational clone that enables it to proliferate, invade, and overcome its
immune environment [1]. These mutational clones lead to heterogeneity, contributing to
the challenges in selecting targeted treatment. A better understanding of the mutational
landscape and personalized treatment is necessary. The advent of precision medicine
has led to the identification of actionable driver mutations regardless of tumor site or
origin [2]. The presence of this Darwinian dynamic drives cancer evolution in the process
of natural selection of “driver” somatic mutations that give rise to persisting epigenetic
changes responsible for proliferation and tumorigenesis [3,4]. The identification and the
classification of these mutational drivers has unlocked the potential to therapeutically
inhibit this process of perpetual autonomous expansion through targeted therapy [5–9].
The major NCI-MATCH study showed that molecular profiling was successful in 93%
of cases, and an actionable alteration was identified in almost 40% of patients [2]. These
results affirm the promise of precision medicine to transform clinical approaches from
an organ-focused model to a comprehensive mutational signature model of cancer care.
However, the application of targeted therapy across solid tumors has not been previously
described in a real-world scenario. In this study, we have assessed and characterized
the genomic and therapeutic landscape of a cohort of solid metastatic tumors at a single
academic site. We performed a retrospective cohort analysis of 957 patients from seven
major cancer groups who received next-generation sequencing (NGS) to investigate the
relationship between alterations and overall survival (OS). The utilization of a single panel,
FoundationOne CDx®, allowed us to independently evaluate the heterogeneity of our
cohort, as well as to understand the alteration frequencies and their involvement in cancer
diagnosis, progression, and OS.
2. Materials and Methods
2.1. Patient Characteristics
Patients (N = 1001) with solid tumors who underwent a commercial NGS molecular
testing panel (Foundation Medicine, Cambridge, MA, USA) at City of Hope (COH) between
2010 and 2018 were evaluated. FoundationOne CDx® assay is a clinically and analytically
valid somatic mutation detection assay approved by FDA in November 2017 for all solid
advanced tumors. Using their proprietary DNA extraction method from formalin-fixed
paraffin-embedded (FFPE) tumor tissue samples, FoundationOne CDx® can detect single
nucleotide variants (SNVs), insertion-deletions (indels), and copy number alterations
(CNAs) in 324 genes, as well as select rearrangements in 36 genes, microsatellite instability
(MSI), and tumor mutational burden (TMB). Unlike hotspot tests, FoundationOne CDx®
offers comprehensive genomic profiling of the included genes. Therefore, the risk of
selection bias of actionable mutation in this study is minimal with this assay for the solid
cancer types analyzed. The COH patients with solid cancer with available FoundationOne
CDx® testing reports were eligible for evaluation in this study. The inclusion criteria for the
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current study include metastatic disease of solid cancers and availability of FoundationOne
CDx® test results after metastatic diagnosis. Cancer types that had less than 15 samples or
samples that had an unknown date of metastatic disease diagnosis were excluded from the
analysis. The majority of the specimens were collected from the primary sites as shown in
Supplemental Table S1. Based on the inclusion-exclusion criteria, 957 patients were eligible
for the study (Supplemental Figure S1). The clinical data collected from the electronic
health record (EHR) included sex, age at diagnosis, date of metastatic diagnosis, race, stage,
vital status at last contact, date of death/last contact, histology, cancer type, specimen type,
date of molecular testing sample collection and results, first-line treatments, progression-
free survival (PFS) and OS. The study was approved by the COH Institutional Review
Board (IRB #18038) and the Department of Health and Human Services. The study was
conducted according to the standards of Good Clinical Practice, the Declaration of Helsinki,
and the US Department of Health and Human Services. All patients were evaluated for
their written consent or exemption of consent according to requirements of the IRB and
ethics committees, and all recorded data for this study were deidentified.
2.2. Statistical Analysis
Patient demographics and somatic mutations were summarized using descriptive
statistics. Wilcoxon rank-sum test was used to compare the frequencies of mutations in
two independent metastatic cohorts, specifically the COH pan-cancer and the University
of Michigan 2017 metastatic cancer cohorts [10]. We evaluated mutation frequencies, co-
occurrence, mutual exclusivity, and prognostic values. Cox regression models were used
for univariate and multivariate analysis of OS endpoints with complete observations for
clinical variables considered. For the mutation-based survival analysis, somatic mutations
in 27 genes with 95 or more occurrences in the cohort were considered, and p < 0.0017
(Bonferroni corrected for multiple testing) was considered to be significant for survival
analyses using the Kaplan–Meier log-rank test. Mutations in >35 patient cases were
considered for both co-occurrence and mutual exclusivity analysis. For multiple testing
corrections, a false discovery rate (FDR) < 0.01 was considered to be statistically significant
for analyses of co-occurrence and mutual exclusivity. For all other survival analyses, p < 0.05
was deemed to be significant. For pairwise OS comparison of APC and CDKN2A mutation
statuses, Log-Rank test with Bonferroni adjusted p value was used for the significance
test. Time to test was calculated in days between the date of metastatic diagnosis and
FoundationOne CDx® report date. Student t-test was used to evaluate times to test between
pre-2015 and 2015 or later metastatic diagnosis. OS days were calculated from the date of
metastatic diagnosis to the date of last follow-up, while PFS days were calculated from
the date of metastatic diagnosis to the date of progression after first-line interventions.
Data regarding PFS was obtained from the electronic medical record based on the primary
oncologist’s notes and assessment of progression. We also compared our cohort to the
mutation case frequencies from the Genomic Data Commons (GDC) and 500 adult patients
with solid metastatic tumors [10,11].
The R packages used were ComplexHeatmap, GenVisR for heatmap analyses, discover
for mutation co-occurrence and mutual exclusivity, and survival and survminer for OS
analysis [12–17]. All analyses were performed using R version 3.6.2 [18].
3. Results
3.1. Clinical and Genomic Features
Of the 957 patients included in the analysis, 51.9% were female, and 69.7% were
Caucasian. The median age at diagnosis was 60 years (IQR: 50–69 years) (Table 1). Seven
major cancer diagnosis were included-breast (9.1%), colorectal (33.6%), gastrointestinal (GI;
12.9%), genitourinary (GU; 12.3%), gynecological (GYN; 6.2%), head and neck (H&N; 2%),
and thoracic (23.9%) cancers. Colon adenocarcinoma (274, 28.6%) and lung adenocarcinoma
(171, 17.9%) were the most common cancer subtypes in the cohort. A total of 390 (40.6%)
patients harbored at least one targetable somatic mutation in actionable genes—AKT1,
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ATM, ALK, BRAF, BRCA1, BRCA2, EGFR, ERBB2, ESR1, FGF3, FGFR1, FGFR2, FGFR3,
MET, NTRK1, NTRK2, NTRK3, PIK3CA, ROS1, and RET (NCCN colon, esophagus, head
and neck, kidney, lung, ovary, prostate, urinary tract, and uterus guidelines; accessed
on 13 December 2020) [19]. The most frequently altered gene in the COH pan-cancer
cohort was TP53 (57.3%), followed by APC (31%) and KRAS (27%). In the COH cohort,
TP53 alterations were the most prevalent in all cancer types except GU cancers (Figure 1,
Supplemental Table S2). Colorectal cancer had the highest frequencies of TP53, APC, and
KRAS mutations (76.4%, 73.9%, and 47.8%, respectively). H&N cancer had the highest
frequencies of LRP1B (31.6%), and breast cancer had the highest frequency of PIK3CA and
MYC (32.2% and 28.7%, respectively). Additionally, the COH pan-cancer cohort and the
University of Michigan 2017 metastatic cancer cohort were significantly different within
the top eleven common mutation frequencies (Figure 1B, Wilcoxon rank-sum test p 0.016).
TP53, KRAS, and APC mutation frequencies were higher in the COH compared to the
University of Michigan cohort [10]. In comparison with the GDC cancer types, TP53 was
the most frequently altered mutation (35%). However, TP53 mutations occurred at a much
higher rate in the COH cohort than the University of Michigan metastatic cohort (49%)
and other primary tumor cohorts of TCGA (41%), TCGA 27.0 (36.6%), GENIE 8.1 (39%),
and PCAWG (36.9%) [20–23]. The second most prevalent altered gene in our cohort was
APC (31%), which was over 20% higher than the next highest dataset when compared
to the University of Michigan metastatic cohort (0.07%) and mixed cohorts from TCGA
(8%), TCGA 27.0 (8.1%), GENIE 8.1 (10.3%), and PCAWG (3.4%) [20–23]. The next most
prevalent altered gene was KRAS (27%), which was 12% higher than TCGA (7%), TCGA
27.0 (9.8%), GENIE 8.1 (15.1%), and PCAWG (11.1%) [20–23].
3.2. Co-Occurrence and Mutual-Exclusivity in Pan-Cancer Cohort
There were 147 somatic mutations detected with more than 35 mutation cases within
the cohort. Seven gene-pairs were found to be mutually exclusive and 51 gene-pairs to be
co-occurring (Supplemental Table S3). Of the mutually exclusive pairs, KRAS was mutually
exclusive with EGFR, ERBB2, and VHL. APC was mutually exclusive with CCDN1 and
CDKN2A. Of these seven pairs, a groupwise mutual exclusivity analysis with eight genes
(KRAS, EGFR, ERBB2, VHL, RB1, APC, CDKN2B, CCND1) were also mutually exclusive
(p < 0.0001, Figure 2). Alternatively, ARFRP1, ASXL1, AURKA, BCL2L1, GNAS, SRC,
TOP1, ZNF217 were the most commonly co-occurring, with each co-occurring with seven
other genes (FDR < 0.01). Of the actionable genes, BRCA2, ERBB2, and MYC co-occurred
with CDK8, CDK12, and RUNX1T1, respectively.
3.3. Survival Analysis
The COH metastatic solid cancer patients had a median PFS and OS of 10 months and
27 months, respectively. Out of 957 patients, 831 patients progressed despite the first-line
interventions with pharmacotherapy, surgery, or radiation and 44 patients (21 colorectal,
4 GI, 7 GU, 2 gynecological, 10 thoracic cancer patients) did not progress. The remaining
82 patients had an unknown status of progression. The presence of APC (HR: 0.68, 95%
CI: 0.54–0.85, p < 0.0001) and CDKN2A (HR: 2, 95% CI: 1.6–2.6, p < 0.0001) was significant
predictors of the longer and shorter OS, respectively. However, only CDKN2A status
remained significant (HR: 1.72, 95% CI: 1.34–2.21, p < 0.001, Supplemental Figure S2) after
adjusting for age at metastatic diagnosis, gender, and cancer type in the multivariate Cox
regression models. Due to the small number of patients with stable disease or remission,
PFS was not significantly associated with any somatic mutation status. Patients with
APC+/CDKN2A- metastatic cancer survived significantly longer than the patients who
are APC-/CDKN2A+ (median survival 52 months compared to 20 months, p < 0.0001,
Figure 3). Although APC and CDKN2A co-mutations are rare and have contrasting effects
on OS, patients with APC mutation showed statistically nonsignificant longer OS in the
presence of CDKN2A (median survival 34 months with APC+/CDKN2A+ mutations
compared to 20 months with APC-/CDKN2A+ mutations).
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Table 1. Baseline characteristics of 957 patients with seven metastatic solid cancers. IQR: interquartile range; MSI: microsatellite instability.








(n = 19) Thoracic (n = 229)
Age at diagnosis,
median (IQR) 60 (50–69) 50 (42–56) 56 (48–66) 63 (49–70) 67 (60–73) 61 (51.5–71) 61 (50.5–65.5) 64 (54–72)
Race, n (%)
White 667 (69.7) 50 (57.5) 230 (71.4) 74 (60.2) 98 (83.1) 47 (79.7) 17 (89.5) 151 (65.9)
Asian 194 (20.3) 18 (20.7) 60 (18.6) 35 (28.5) 13 (11) 8 (13.6) 1 (5.3) 59 (25.9)
African American 47 (4.9) 12 (13.8) 15 (4.7) 4 (3.3) 2 (1.7) 2 (3.4) 1 (5.3) 11 (4.8)
Other 18 (1.9) 4 (4.6) 7 (2.1) 7 (5.7) 3 (2.5) 2 (3.7) 0 (0) 4 (1.7)
Unknown 22 (2.3) 3 (3.5) 10 (3.1) 3 (2.4) 2 (1.6) 0 (0) 0(0) 4 (1.7)
Ethnicity, n (%)
Hispanic or Latino 193 (20.2) 24 (27.6) 74 (23) 37 (30.1) 10 (8.5) 16 (27.1) 3 (15.8) 29 (12.7)
Not Hispanic
or Latino 752 (78.6) 61(70.1) 244 (75.8) 83 (67.5) 108 (91.5) 43 (72.9) 16 (84.2) 197 (86)
Unknown or
not disclosed 12 (1.2) 2(2.3) 4 (1.2) 3 (2.4) 0 (0) 0 (0) 0 (0) 3 (1.3)
Sex, n (%)
Female 497 (51.9) 87 (100) 138 (42.9) 54 (43.9) 27 (22.9) 59 (100) 8 (42.1) 124 (54.1)
Male 460 (48.1) 0 (0) 184 (57.1) 69 (56.1) 91 (77.1) 0 (0) 11 (57.9) 105 (45.9)
Tumor Burden, n (%)
Low 204 (21.2) 19 (21.8) 70 (21.7) 20 (16.3 16 (13.1) 21 (35.6) 10 (52.6) 48 (21.1)
Intermediate 115 (12) 6 (6.9) 37 (11.5) 17 (13.8) 8 (6.6) 10 (16.9) 3 (15.8) 34 (14.9)
High 17 (1.8) 0 (0) 2 (0.6) 1 (0.8) 1 (0.8) 1 (1.7) 2 (10.5) 10 (4.4)
Unknown 624 (65) 62 (71.2) 221 (66.1) 85 (69.1) 97 (79.5) 27 (45.8) 4 (21.1) 136 (59.6)
Stage at initial
diagnosis, n (%)
I 41 (4.3) 16 (18.4) 9 (2.8) 0 (0) 0 (0) 5 (8.5) 1 (5.3) 10 (4.4)
II 81 (8.5) 32 (36.8) 29 (9) 2 (1.6) 0 (0) 4 (6.8) 3 (15.8) 11 (4.8)
III 134 (14) 23 (26.4) 62 (19.3) 3 (2.4) 4 (3.9) 23 (39) 0 (0) 19 (8.3)
IV 701 (73.3) 16 (18.4) 222 (68.9) 118 (95.9) 114 (96.6) 27 (45.8) 15 (78.9) 189 (82.5)
MSI status, n (%)
High 8 (0.8) 0 (0) 2 (0.6) 2 (1.6) 0 (0) 1 (1.7) 1 (5.3) 2 (0.9)
Stable 351 (36.7) 26 (29.9) 116 (36) 39 (31.7) 25 (21.2) 32 (54.8) 15 (78.9) 98 (42.8)
Unknown 598 (62.5) 60 (70.1) 204 (63.4) 82 (66.7) 93 (78.8) 26 (44.1) 3 (15.8) 129 (56.3)
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Figure 1. Mutation analysis of 957 patients treated at City of Hope. (A) Co-mutation plot of all somatic mutations with a 
frequency of 6% or more in 957 metastatic cancer patients. Row percentages represent the frequency of gene mutations in 
Figure 1. Mutation analysis of 957 patients treated at City of Hope. (A) Co-mutation plot of all
somatic mutations with a frequency of 6% or more in 957 metastatic cancer patients. Row percentages
represent the frequency of gene mutations in the cohort. Each of the column bars represents the
number of mutations for each patient. SNV: single nucleotide variants; VUS: variant of unknown
significance; GI: gastrointestinal; GU: genitourinary. (B) Comparison of most frequent mutations from
the City of Hope 2020 and University of Michigan 2017 cohorts of solid metastatic cancer patients.
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co-occurring gene pair were identified. ARFRP1, ASXL1, AURKA, BCL2L1, GNAS, SRC, TOP1, ZNF217 were most com-
monly co-occurring, and each co-occurred with seven other genes (FDR < 0.01). 
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maining 82 patients had an unknown status of progression. The presence of APC (HR: 
0.68, 95% CI: 0.54–0.85, p < 0.0001) and CDKN2A (HR: 2, 95% CI: 1.6–2.6, p < 0.0001) was 
significant predictors of the longer and shorter OS, respectively. However, only CDKN2A 
status remained significant (HR: 1.72, 95% CI: 1.34–2.21, p < 0.001, Supplemental Figure 
S2) after adjusting for age at metastatic diagnosis, gender, and cancer type in the multi-
variate Cox regression models. Due to the small number of patients with stable disease or 
remission, PFS was not significantly associated with any somatic mutation status. Patients 
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Figure 2. Mutually exclusive and co-occurring genes. Genes with more than 35 positive mutation cases were considered.
Chord iagrams of (A) mutually exclusive, and (B) co-o curring gene pairs with a false discovery rate (FDR) less than 0.01.
The arcs shown in the scaled chord-diagram between he pairs of genes repr ent the mutual exclusivity or co-occurren e.
There were seven mutually exclusive gene pairs, of which KRAS was mutually exclusive with EGFR, ERBB2, and VHL.
APC was mutually exclusive with CCND1 and CDKN2A. Thirty-one co-occurring gene pairs with more than one co-
occurring gene pair were identified. ARFRP1, ASXL1, AURKA, BCL2L1, GNAS, SRC, TOP1, ZNF217 were most commonly
co-occurring, and each co-occurred with seven other genes (FDR < 0.01).
3.4. Effect of Molecular Testing and First-Line Treatments
The median time from initial metastatic diagnosis to molecular testing was 265 days
(IQR: 75–639 days) with a significantly accelerated time to testing since 2015 (mean
200.9 days compared to 890.6 days prior to 2015, p < 0.0001). The median time to re-
porting from sample collection was 115 days (IQR 41–401 days) and was significantly
associated with time to testing (Pearson’s correlation: 0.46; p < 0.0001). Five-year post
metastatic diagnosis survival analysis showed a significant improvement in OS (median
survival 28 and 43 months in pre-2015 and post-2015 metastatic diagnosis, respectively,
p 0.00021) by the year of metastatic diagnosis potentially due to faster time to testing and
availability of targeted therapy based on the test results (Supplemental Figure S3).
First-line treatment information was available for 941 (98.3%) patients, with 387 (40.4%)
patients receiving targeted therapies as a first-line treatment after metastatic diagnosis. Of
the known first-line treatments received by these patients, 5-FU, leucovorin, oxaliplatin,
bevacizumab, irinotecan, capecitabine, and carboplatin were among the most frequently
used chemotherapies across all seven cancer types (Figure 4). These drugs were most
commonly used in colorectal and GI cancers. Carboplatin and pemetrexed regimen were
most frequently administered in thoracic cancer. Although patients who received a targeted
therapy as a first-line treatment after metastatic diagnosis tended to have a longer 5-year
OS (45 months compared to 37 months for patients who received traditional therapies), the
survival difference was not statistically significant (p = 0.072, Figure 5A). However, PFS
was significantly longer for patients who received targeted therapies compared to patients
who received traditional therapies such as chemotherapies, surgery, or radiation (median
PFS 10.9 months [CI: 9.7–11.9 months] compared to 9.1 months [CI: 8.1–10.1 months],
respectively, p 0.0029, Figure 5B). Use of targeted therapies as first-line treatment remained
significantly associated with PFS (HR 0.81; 95% CI: 0.69–0.94; p 0.007) after adjusting for
patient’s cancer type, age at diagnosis, and sex.
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4. Discussion
Treatment of metastatic cancer continues to be challenging, resulting in high mortality
among all cancer patients [24]. Here, we analyzed 957 metastatic solid cancer patients
treated at the COH. In comparison with other published pan-cancer datasets, including
The Cancer Genome Atlas (TCGA), the Pan-Cancer Analysis of Whole Genomes (PCAWG),
and the recent data releases for the Genomics Evidence Neoplasia Information Exchange
(GENIE) 8.1 and TCGA 27.0, there was significant variation in top somatic mutation
frequencies of TP53, APC, KRAS, and LRP1B genes [20–23]. One possible explanation
for the differences in frequency is the metastatic status of our cohort compared to the
mixed cancer patient population from TCGA 27.0 and GENIE. Further, there were only
957 patients in our COH cohort, while the most recent data releases for TCGA 27.0 and
GENIE 8.1 were for 84,392 and 95,918 primary tumor samples, respectively [21,22,25]. Also,
we analyzed breast, colorectal, gastrointestinal, genitourinary, gynecological, head and
neck, and thoracic major cancer types. Colorectal (322, 33.6%) and thoracic (229, 23.9%)
accounted for 57.5% of all cancer diagnosis in our cohort, and TP53, APC, KRAS, and
LRP1B mutation rates are higher in colorectal cancers and non-small cell lung cancers
(NSCLC) [26–29]. APC gene mutations are known to be associated with chromosomal
instability, however, similar to our findings several studies have identified that mutated
APC was associated with improved survival as compared to wild-type APC in colorectal
cancer [30–34].
Mutual exclusivity and co-occurrence among oncogenic driver mutations warrant
careful discussion when considering targeted therapies and treatment plans. While biology
drives mutual exclusivity, most co-occurrences are most likely by chance [14]. Previous
studies have reported the prevalence of concomitant driver mutations among the different
patient populations. In our study, the seven mutually exclusive gene pairs with FDR < 0.01
are KRAS/EGFR, CDKN2A/APC, KRAS/ERBB2, VHL/TP53, RB1/CDKN2B, VHL/KRAS,
and CCND1/APC. A well-known pair of genes that validates our mutual exclusion data
is KRAS with mutated EGFR loci, most commonly seen in lung cancer [35]. The EGFR
family of receptors EGFR and HER2 (ERBB2) act as upstream regulators of KRAS in the
Ras/Raf/MEK/ERK pathway. Concurrent mutations in EGFR or ERBB2 and KRAS are
not selected for and may be considered redundant in tumor cells, thus selective pressures
may account for the mutual exclusivity of EGFR/ERBB2 and KRAS [36–38]. However,
recent publications have shown small cohorts of patients that harbor the rare EGFR/KRAS
co-mutations. Zhuang et al. reported a comprehensive study analyzing concomitant driver
gene mutations in 3774 NSCLC Chinese patients harboring EGFR, ALK, ROS1, KRAS, and
BRAF alterations. Only 63 patients (1.7%) harbored mutations in two or three of these genes
and among these patients, EGFR/KRAS was the most frequent co-alteration (31.7%) [39].
Pesek et al. reported four clinical cases of NSCLC patients with confirmed co-mutations in
four of the five clinical cases presented [40]. Additionally, our analysis confirmed that the
presence of TP53 mutations was mutually exclusive with VHL mutations. Previously, it
was found that mutual exclusivity among the mutations depends on different histological
subtypes in renal cell carcinomas (RCCs) [41]. Szymańska et al. reported 77% of clear-cell
carcinomas from a multi-center case-control study harbor VHL mutations; in contrast, only
22% of RCCs of other histological types harbor VHL mutations [42]. Upon stratification,
clear cell tumors showed mutual exclusivity among TP53 and VHL mutations, whereas
non-clear cell tumors had TP53 mutations in the absence of VHL mutations.
We reported the following actionable gene pairs as co-occurring—ERBB2/CDK12,
BRCA2/CDK8, and MYC/RUNX1T1 with additional gene pairs, including PREX2/RUNX1T1
and STK11/KEAP1. Somatic mutations that co-occur are common across various cancer
types. For example, CDK12 is an essential transcription-associated CDK responsible for
DNA damage response and is often found in the ERBB2 amplicon [43–45]. Capra et al.
reported that CDK12 gene amplification can often co-occur with ERBB2 amplification and
may act as an oncogenic driver in HER2-positive breast cancer [46–48]. Wilson et al. re-
ported similar co-occurring gene pair mutations among breast cancer subtypes (HER2+, hor-
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mone receptor positive [HR+], and triple-negative breast cancer [TNBC]) [49]. Interestingly,
the commonly occurring gene pairs MYC/RUNX1T1, PREX2/RUNX1T1, PRKDC/PREX2,
and MYC/PREX2 in our study are coamplified genes on the same loci, within the 8q
loci, and reported by Wilson et al. in 13% of patients with HR+, HER2- disease and
19% with TNBC [49]. Lastly, our analysis showed STK11/KEAP1 co-occurring mutations
(FDR < 0.01). Concurrent mutations in STK11/KEAP1 act as a major driver in primary re-
sistance to PD1 blockade in KRAS-mutated lung adenocarcinoma [50]. Papillon-Cavanagh
et al. investigated the utility of STK11/KEAP1 mutations as predictive biomarkers in
patients diagnosed with stage IIIB, IIIC, IVA, or IVB non-squamous NSCLC. It was de-
termined that the co-occurring mutations were associated with poor prognosis in both
anti-PD-1/PD-L1 treated and chemotherapy-treated populations [51].
Rapid advancements in NGS technology have allowed physicians to understand
in real-time the genetic makeup of a patient’s tumor and track these alterations over
time [52–54]. Groisberg et al. reported the identification of an oncogenic mutation in at
least 92% of patients [55]. In a more comprehensive analysis of 10,000 patients, Zehir et al.
reported 91% successful sequencing and identified 36.7% of patients with at least one
actionable alteration [56]. These rates of actionable alterations were previously estimated
to be lower, but recent studies show that actionability in solid tumors can vary between
35–80% [57–61]. This has been compounded by the recent results from the NCI-match
study that sequenced 93% of 5954 patients and identified actionable alterations in 37.8% of
cases [2]. Our results suggest a similar frequency to other NGS-guided studies that match
targeted therapy based on the identification of at least one actionable alteration [62,63].
The advent of novel therapeutics, including new NTRK, RAS, RET, and MET inhibitors has
transformed the clinical trial landscape and presented more therapeutic options to patients
than ever before [64–67]. These advancements in genomic sequencing and trial accrual
validate precision medicine to deliver improved outcomes in all solid tumors.
It is worth noting that our study has several limitations. First, this is a retrospective
cohort study using seven solid metastatic tumor patients from a single center. Therefore,
the study results may not be generalizable to other metastatic cohorts. Second, survival may
depend on various factors beyond the age of diagnosis, sex, cancer type, and treatments
used. Also, treatment options are different depending on cancer types, and the efficacy
of treatments may vary significantly based on how soon in the disease progression they
were initiated. Therefore, our survival assessment was oversimplified. Third, we did not
capture clonal heterogeneity and evaluate the effect of intratumor heterogeneity on OS.
Future studies need to address these limitations in the evaluation of somatic mutations in
solid metastatic pan-cancer patients.
5. Conclusions
The promise of precision medicine relies on identifying mutations in patients and
developing novel therapeutics for these drug targets. Beyond actionable mutations, gene
expression and epigenetics data may further elucidate critical pathway activation and
identify potential targeted therapies [68,69]. Although gene expression and epigenetics
data are not routinely implemented in clinical decision-making, using these in collabo-
ration with mutation data will shed light on the selection of optimal targeted therapies
and potentially avoid resistance development. Targeted therapies are becoming more
common and the efficacy of these agents has been proven in several solid tumors [67,70–76].
These agents provide a measurable outcome advantage compared to other therapeutic
options, including chemotherapy and immunotherapy—with the longest median OS of
7 years in patients with ALK-mutated metastatic NSCLC, an achievement unmatched by
any other therapeutic option [77]. However, the primary barrier to targeted therapeutics
remains acquired resistance due to evolutionary competition between resistant and sensi-
tive subclones, which leads to survival of persistent subclones that alter tumor behavior
and outcomes [78–81]. Our results showed the application of targeted therapies improved
PFS, potentially owing to early testing and availability of increasing number of targeted
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therapies. Combinatory targeted therapeutic options are a potential non-toxic avenue for
combatting this resistance, and several early and late-stage clinical trials, including NCI
#10327, NCI #9466, and NCT03944772, are currently underway to understand their efficacy.
The promise of precision medicine is quickly transforming into the reality of precision
therapeutics with the discovery of effective KRAS-inhibitors and other drug targets that
were previously thought to be undruggable [65,71]. Therefore, the outcomes of patients
with solid tumors rely on the successful inhibition of oncogenic mutational signatures that
drive disease progression by utilizing informed targeted therapy.
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